You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
SBC: Cyteir Therapeutics, Inc. Topic: NCI
DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NeuroSigma, Inc. Topic: 101
DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: SILVER LAKE RESEARCH CORPORATION Topic: NIAID
PROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health